Therapeutics Hormonal Agents

Preliminary experience with the use of human chorionic gonadotrophin therapy in women with repeated abortion

Svigos J

Published June 1982 Clinical Reproduction and Fertility, 1(2), 131-135
PMID 6892271

Abstract

A preliminary study of 'screened' women with two consecutive miscarriages revealed an incidence of abortion in 47.4% in a subsequent pregnancy whilst hCG therapy in a similar group of women where biochemical monitoring with plasma progesterone suggested a potentially jeopardized pregnancy resulted in a continuing pregnancy in 92.3% of treated women. An urgent need for a true randomized double-blind evaluation of this therapy has been established in order to re-examine the therapeutic nihilism which currently pervades the management of women with recurrent abortion.

Read the guide

  • Miscarriage and Recurrent Pregnancy Loss: The Workup Most Women Never Get

    Miscarriage affects approximately 15% of clinically confirmed pregnancies. Recurrent pregnancy loss (RPL), defined as two or more clinical losses, affects 2 to 5% of couples. Most causes are diagnosable and treatable. This guide covers what the standard workup misses, what RRM-trained clinicians evaluate, and what outcomes look like after cause-based treatment.

    22 min read

Topics

Related research

Therapeutics › Hormonal Agents › Gonadotropins · Pregnancy › Early Pregnancy › Miscarriage · Reproductive Endocrinology › Luteal Phase › Luteal Phase Deficiency
PMID 6892271 6892271 Svigos et al. 1982, Svigos 1982